Switch that regulates the production of the protein E-Cadherin, the loss of which is a prerequisite for prostate cancer metastasis has been discovered by scientists.
The transcription factor SPDEF turns on and off production, leading to metastasis or stopping it cold in models of prostate cancer.
Prostate Cancer: Treatment Options
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.
Advertisement
"When E-Cadherin is lost, cells become 'rouge' - they can detach from their surrounding tissues, move effortlessly through the circulatory system, grow and attach at new sites," said Hari Koul, PhD, investigator at the CU Cancer Center and professor and director of Urology Research at the University of Colorado School of Medicine, the study's senior author.
"In prostate tumors that had lost E-Cadherin, we put in SPDEF and the tumors once again expressed E-Cadherin. They were once again anchored in place and unable to metastasize. We can make these 'rouge' cells back into epithelial-like cells and these epithelial cells stay anchored and lose the ability to migrate," added Koul.
![Quiz on Prostate Cancer]( "Quiz on Prostate Cancer")
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it's too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!
In fact, the work could have implications far beyond prostate cancer, as increasing evidence points to loss of E-Cadherin as a prerequisite for metastasis in many cancers.
Koul and colleagues first showed that E-Cadherin levels varied directly with the addition or subtraction of SPDEF. Then the group artificially knocked down E-Cadherin despite the presence of SPDEF and showed that cells remained able to migrate and invade new tissues (SPDEF didn't by itself affect metastasis and was instead dependent on modulating E-Cadherin, which is the driver).
The group also showed a one-way switch - SPDEF regulates E-Cadherin, but E-Cadherin expression does nothing to affect levels of SPDEF.
"Taken together, these studies paint a pretty compelling picture of SPDEF working in part through the modulation of E-Cadherin to inhibit prostate cancer metastasis," Koul said.
"To the best of our knowledge these are the first studies demonstrating the requirement of SPDEF for expression of E-Cadherin," he added.
Koul stated that his group is getting very close to turning off the loss of E-Cadherin in cancer cells by re-arming tumors with the gene that makes SPDEF and my testing small molecules that increase SPDEF in cancer cells.
The study was published in the Journal of Biological Chemistry.
Source: ANI
Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it's too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!
Advertisement
In fact, the work could have implications far beyond prostate cancer, as increasing evidence points to loss of E-Cadherin as a prerequisite for metastasis in many cancers.
Koul and colleagues first showed that E-Cadherin levels varied directly with the addition or subtraction of SPDEF. Then the group artificially knocked down E-Cadherin despite the presence of SPDEF and showed that cells remained able to migrate and invade new tissues (SPDEF didn't by itself affect metastasis and was instead dependent on modulating E-Cadherin, which is the driver).
The group also showed a one-way switch - SPDEF regulates E-Cadherin, but E-Cadherin expression does nothing to affect levels of SPDEF.
"Taken together, these studies paint a pretty compelling picture of SPDEF working in part through the modulation of E-Cadherin to inhibit prostate cancer metastasis," Koul said.
"To the best of our knowledge these are the first studies demonstrating the requirement of SPDEF for expression of E-Cadherin," he added.
Koul stated that his group is getting very close to turning off the loss of E-Cadherin in cancer cells by re-arming tumors with the gene that makes SPDEF and my testing small molecules that increase SPDEF in cancer cells.
The study was published in the Journal of Biological Chemistry.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
![Prostate Specific Antigen [PSA]](https://www.medindia.net/images/patientinfo/120x100/prostate-specific-antigen.jpg "Prostate Specific Antigen [PSA]")
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable